ȿռԤΤ
ץ

ޡȥץȾϤޤӥͥޥȿŪʤʤΤ긵ء

2012ǯ05

ϡۥե륻 ˤĤƤΤäĹǤ


ۥե륻ϡ˦ΤҤȤġ


ʹ֤κ˦ϡ٤ƤλޤǤꡢ¸ɬפʵǽϡΥۥե륻äƤ롢ȸȤǤޤ


ȤС̿ưΥͥ륮λ (ATP)


̿ǽݤĤΥΥۥᥪǽ


˦٥ǤγԳʤɤʤɡ


ƥۥե륻ϡȤˡк˦䥷ʥץ¿¸ߤ[1]


륳ɡѥߥ󡢥Υ륢ɥʥȤäãʪФ䥷ʥã˴ͿƤޤ[2,3,4,5]


ۥե륻ΡƬǾؤͭˤĤơʳŪϼθ̤𤷤Ƥޤ


Ϥβ


ݸ


ȥ쥹


ĺ


ƬǾη򹯤ˤʤˡۥե륻ϡǤ֤ǤϤʤǤ礦



ǤϡʸϤǤ礦


ʿǯ20.4Фηͤоݤˤ祦եȥۥե륻ȤȤ߹碌ĴΤǤ


Ȥ߹碌Ϥ


1) 祦ե120 ñΤݼ褷硣


2) 祦ե120 ȥۥե륻 (PS) 360 Ʊݼ褷硣


3) 祦ե120 ȥۥե륳 (PC) 360 Ʊݼ褷硣


λѥǡָ


ϤΥԡɡ


Ϥ


ֵϤΥԡɡ


ֵ


󼡵


֥󥰥꡼ Ĵ٤Ƥޤ





) 祦եȥۥե륻 Ȥ߹碌Ǥ̤ι⤤Ȥ߹碌ä褦Ǥ


ϤΥԡɡ ˤƤ

祦եñȤ1) ȥ祦եPC3) 2.5ָޤͭդ®ʤä


祦եPSƱݼ 2) ϡˡ6ָˤƤͭդ®


Ϥ Ǥ


祦եPS 2) Ȥ߹碌ͭդʲߤ줿


ֵΥԡɡ Ǥ


祦եPC 3) 4ָ˵դ٤ʤä祦եPS 2) ϡݼ裱֤飶ָΤ٤Ƥͭդ˲[6]


Υȥϡͤ˽񤭴٤⤷ޤ


ƬǾη򹯤ˤϡۥե륻ȥ祦եĤʻݤ٤Ǥ


ǤϤʤۥե륻ϵϤΤǤ礦


Υᥫ˥Τʲ̤ʤƤϤޤ󤬡ˤʤ뤫Ȼפޤ


륳ưʥץǽγ [7]


ʥãϤؤθ [8] [9]


ޤۥե륻ϡݸѤͭƤޤ


ʥͥߤ˥ۥե륻 (200mg/kg,5) 򤢤餫ͿƤ顢ǾƣˡCA1ΰ (ξϵˤϽפΰǤ) οк˦ؤθ̤Ĵ٤


ȥۥե륻Ϳϡץ饻ܷ١к˦ؤΥ᡼ڸƤ[10]


ۤˤDz٤αɤ򵯤ǾȿФ (ȱֺ˦ȿ򹶷⤹륱) ۥե륻ϤαɤƯ򤷤Ƥޤ[13]


ˡۥե륻ϿĹҼοäޤ


Ĺ (Nerve growth factor: NGF) Ͽȯã򤦤ʤǽϤ餫륿ѥǤ[14]


ΤϤ餭NGF ( ϤǾοк˦ɽ̤¸ߤ) NGF礹뤳ȤˤäƵޤ


NGFοϲȼ뤳ȤʬäƤޤ


åȤμ¸ˤƥۥե륻ϡNGFοäƤޤ[15]

ϡк˦ιϷѤ̣Ƥޤ


ƱʸˤϡεҤ⸫ޤ


ˤäƿк˦μ͵Υѥ̩١˥塼ο礭ϸƤ椭ޤϷͥߤ˥ۥե륻 (50mg/kg,24) Ϳ̤ǤϡΤ褦ʸǧʤä[15]


ޤۥե륻ιȥ쥹Ѥ⸫ƨȤϤǤޤ


ȥ쥹ˤϡ뤬ޤ


ΥۥμΤϡǾ (Ȥ˳) ʢ¿ȤΤƤޤ


ȥ쥹Ͽ徺׹ͤᤰ餻ʢˤϤäפȻä򤿤ᤳޤ롣


ͶƳ⡢ΰǤ


ʥϡк˦ˤͭǤ


Ϥοк˦μΤɷ㤷ֶʳ 򾷤Ǥ

(ʳȤϡ륷।κ˦ή뤳Ȥǿк˦˻ᥫ˥)


ۥե륻ϤΥβ껺ޤ


ȥȥ졼˥󥰤ǡСȥ졼˥󥰤ˤʤä˥ۥե륻 (800 /) ݼ褷Ȥȯᥫ˥Ǥ뾲--շϤѲ⤿餷뻺㲼[16,17,18]


ˡۥե륻ϡѤͭƤ褦Ǥ


԰¾㳲䤦ľɾβ[20]


ʡҸǽϤξ徺ǧ줿[16,19,20,21]


ȤǡǾͭפȤ륵ץȤФ뺬ŪʵϡʪۤȤǾϤΤ


ä⡢ޤ


ʤʤ顢Ǿؤ̤BBB (Ǿ) ̤ȴ뤳ȤǤ


ۥե륻ϡиݼˤƤ⡢ǾܹǧƤޤ[10]


ǤϺǸ


ۥե륻ϡ̤ǡɤΤ餤̤ݤɤΤǤ礦


ͤϡ100 ʾݼ褬ͭ[22]


ڷ


Ǿη򹯤ˤϡۥե륻100 ݼ褹뤳ȡ


ȥ쥹¿ȿռԤƬǾϡˡ祦ե120 äݤɤǤ礦



ƥSWITCH HYPER SWITCH ϡʬ̤¸Ƥޤ


ʬץˤϥ祦ե120 ȥۥե륻100


ˡɽŪʥޡȥץ긶Ǥͻ200 ȥХѥ˥饨80 ۹礵Ƥޤ


ǾΥѥեޥ󥹤٤ݤϡ SWITCH ƤƤϤǤ礦


SWITCHΥȥ

Amazonڡ
https://www.amazon.co.jp/dp/B0095GON76

HYPER SWITCH Ϥ顪
https://www.amazon.co.jp/dp/B012QKWVMQ


iStock_000005716223XSmall












[1] Kidd PM. 1999. A review of nutrients and botanical in the integrative management of cognitive dysfunction. Altern Med Rev 4:38-43
[2] Bruni A,Toffano G.1982. Lysophophatidylserine, a short-lived intermediate with plasma membrane regulatory properties. Pharmaco Res Commun 14(6):469-484
[3] Yoshimura T, Sone S. 1990 Role of phosphatidylserine in membrane actions of tumor necrosis factor and interfoerons alpha and gamma. Biochem Int 20(4):697-705
[4] Cohen SA,Mueller WE.1992. Age related alterations in the mouse forebrain:partial restoration by chronic phosphatidylserine treatment. Brain Res 584: 174-180
[5] Moynagh PN, Williams DC.1992. Stabilization of the peripheral-type benzodiazepine acceptor by specific phospholipids. Biochem Pharmacol 43(9): 1939-1945
[6] D.O.Kennedy, C.F Haskell, P.L Mauri, A.B Scholey.2007. Acute cognitive effects of standardized Ginkgo biliba extract conplexed with phosphatidylserine. Hum.Psychopharmacol Clin Exp 2007 ;22:199-210
[7] Pedata F et.al. 1985. Phosphatidylserine increases acetylcholine release from cortical slices in aged rats. Neurobiol Aging 6(4): 337-339
[8] Benowitz LI et.al. 2000. GAP-43:an intrinsic determinant of neuronal development and plasticity. Trends Neurosci 20(2):84-91
[9] Gianotti C et.al. 1993. B-50/GAP-43 phosphorylation in hippocampal slices from aged rats: effects of phosphatidylserine administration. Neurobiol Aging 14(5): 401-406
[10] , ƣ . 2010. Ʀۥե륻Ǿǽ Anti-aging Science 2(2): 57-61
[11] Calderon C, Huang ZH, Gage DA, et.al. 1994. Isolation of a nitric oxide inhibitor from mammary tumor cells and its characterization as phosphatidylserine. J Exp Med 180: 945-958
[12] Venema RC, Sayegh HS, Arnal JF, et.al. 1995. Role of enzyme calmodulin-binding domain in membrane association and phospholipid inhibition of endothelial nitric oxide synthase. J Bio Chem 270: 14705-14711
[13] Monastra G,Gross AH, Bruni A et.al. 1993. Phosphatidylserine, a putative inhibitor of tumor necrosis factor, prevents autoimmune demyelinaction. Neurology 43: 153-163
[14] Angelucci L, Ramacci MT, Taglialatela G, et.al. 1988. Nerve growth factor binding in aged rat central nervous system: effect of acetyl-L-carnitine. J Neuroscience Res 20:491-496
[15] Nunzi MG, Milan F, Guidolin D, Toffano G. 1987. Dendritic spine loss in hippocampus of aged rats Effect of brain phosphatidylserine administration. Neurobiol Aging 8:501-510
[16] Cenacchi T, Bertoldin T, Farina C, et.al. 1993. Cognitive decline in the elderly: a double-blind,placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging(Milano) 5:123-133
[17] Monteleone P,Beinat L, Tanzillo C, et.al. 1990. Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. Neuroendocrinology 52:243-248
[18] Monteleone P, Maj M, Beinat L, et.al. 1992. Blunting by chronic hosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharmacol 42:385-388
[19] Maggioni M, Picotti GB, Bondiolotti GP,et.al. Effects of hosphatidylserine therapy in geriatric patients with depressive disdoers. Acta psychiatr Scand 81:265-270
[20] Crook T,Petrie W, Wells C, Massari DC. 1992. Effects of phosphatidylserine in Alzheimers disease. Psychopharmacol 42:385-388
[21] Amaducci L. 1988. Phosphatidylserine in the treatment of Alzheimers disease: results of a multicenter study. Psychopharmacol Bull 24:130-134
[22] Parris M. 1999. A review of nutrients and botanicals in the integratetive management of cognitive dysfunction. Alternative Medicine Review 4(3):144-161

ϡեե륻 ˤĤƤΤäĹǤ


եե륻ϡ˦ΤҤȤġ


ʹ֤κ˦ϡ٤ƤλޤǤꡢ¸ɬפʵǽϡΥեե륻äƤ롢ȸȤǤޤ


ȤС̿ưΥͥ륮λ (ATP)


̿ǽݤĤΥΥۥᥪǽ


˦٥ǤγԳʤɤʤɡ


ƥեե륻ϡȤˡк˦䥷ʥץ¿¸ߤ[1]


륳ɡѥߥ󡢥Υ륢ɥʥȤäãʪФ䥷ʥã˴ͿƤޤ[2,3,4,5]


եե륻ΡƬǾؤͭˤĤơʳŪϼθ̤𤷤Ƥޤ


Ϥβ


ݸ


ȥ쥹


ĺ


ƬǾη򹯤ˤʤˡեե륻ϡǤ֤ǤϤʤǤ礦



ǤϡʸϤǤ礦


ʿǯ20.4Фηͤоݤˤ祦եȥۥե륻ȤȤ߹碌ĴΤǤ


Ȥ߹碌Ϥ


1) 祦ե120 ñΤݼ褷硣


2) 祦ե120 ȥۥե륻 (PS) 360 Ʊݼ褷硣


3) 祦ե120 ȥۥե륳 (PC) 360 Ʊݼ褷硣


λѥǡָ


ϤΥԡɡ


Ϥ


ֵϤΥԡɡ


ֵ


󼡵


֥󥰥꡼ Ĵ٤Ƥޤ





) 祦եȥեե륻 Ȥ߹碌Ǥ̤ι⤤Ȥ߹碌ä褦Ǥ


ϤΥԡɡ ˤƤ

祦եñȤ1) ȥ祦եPC3) 2.5ָޤͭդ®ʤä


祦եPSƱݼ 2) ϡˡ6ָˤƤͭդ®


Ϥ Ǥ


祦եPS 2) Ȥ߹碌ͭդʲߤ줿


ֵΥԡɡ Ǥ


祦եPC 3) 4ָ˵դ٤ʤä祦եPS 2) ϡݼ裱֤飶ָΤ٤Ƥͭդ˲[6]


Υȥϡͤ˽񤭴٤⤷ޤ


ƬǾη򹯤ˤϡեե륻ȥ祦եĤʻݤ٤Ǥ


ǤϤʤեե륻ϵϤΤǤ礦


Υᥫ˥Τʲ̤ʤƤϤޤ󤬡ˤʤ뤫Ȼפޤ


륳ưʥץǽγ [7]


ʥãϤؤθ [8] [9]


ޤեե륻ϡݸѤͭƤޤ


ʥͥߤ˥եե륻 (200mg/kg,5) 򤢤餫ͿƤ顢ǾƣˡCA1ΰ (ξϵˤϽפΰǤ) οк˦ؤθ̤Ĵ٤


ȥեե륻Ϳϡץ饻ܷ١к˦ؤΥ᡼ڸƤ[10]


ۤˤDz٤αɤ򵯤ǾȿФ (ȱֺ˦ȿ򹶷⤹륱) եե륻ϤαɤƯ򤷤Ƥޤ[13]


ˡեե륻ϿĹҼοäޤ


Ĺ (Nerve growth factor: NGF) Ͽȯã򤦤ʤǽϤ餫륿ѥǤ[14]


ΤϤ餭NGF ( ϤǾοк˦ɽ̤¸ߤ) NGF礹뤳ȤˤäƵޤ


NGFοϲȼ뤳ȤʬäƤޤ


åȤμ¸ˤƥեե륻ϡNGFοäƤޤ[15]

ϡк˦ιϷѤ̣Ƥޤ


ƱʸˤϡεҤ⸫ޤ


ˤäƿк˦μ͵Υѥ̩١˥塼ο礭ϸƤ椭ޤϷͥߤ˥եե륻 (50mg/kg,24) Ϳ̤ǤϡΤ褦ʸǧʤä[15]


ޤեե륻ιȥ쥹Ѥ⸫ƨȤϤǤޤ


ȥ쥹ˤϡ뤬ޤ


ΥۥμΤϡǾ (Ȥ˳) ʢ¿ȤΤƤޤ


ȥ쥹Ͽ徺׹ͤᤰ餻ʢˤϤäפȻä򤿤ᤳޤ롣


ͶƳ⡢ΰǤ


ʥϡк˦ˤͭǤ


Ϥοк˦μΤɷ㤷ֶʳ 򾷤Ǥ

(ʳȤϡ륷।κ˦ή뤳Ȥǿк˦˻ᥫ˥)


եե륻ϤΥβ껺ޤ


ȥȥ졼˥󥰤ǡСȥ졼˥󥰤ˤʤä˥եե륻 (800 /) ݼ褷Ȥȯᥫ˥Ǥ뾲--շϤѲ⤿餷뻺㲼[16,17,18]


ˡեե륻ϡѤͭƤ褦Ǥ


԰¾㳲䤦ľɾβ[20]


ʡҸǽϤξ徺ǧ줿[16,19,20,21]


ȤǡǾͭפȤ륵ץȤФ뺬ŪʵϡʪۤȤǾϤΤ


ä⡢ޤ


ʤʤ顢Ǿؤ̤BBB (Ǿ) ̤ȴ뤳ȤǤ


եե륻ϡиݼˤƤ⡢ǾܹǧƤޤ[10]


ǤϺǸ


եե륻ϡ̤ǡɤΤ餤̤ݤɤΤǤ礦


ͤϡ100 ʾݼ褬ͭ[22]


ڷ


Ǿη򹯤ˤϡեե륻100 ݼ褹뤳ȡ


ȥ쥹¿ȿռԤƬǾϡˡ祦ե120 äݤɤǤ礦



ƥSWITCH HYPER SWITCH ϡʬ̤¸Ƥޤ


ʬץˤϥ祦ե120 ȥեե륻100


ˡɽŪʥޡȥץ긶Ǥͻ200 ȥХѥ˥饨80 ۹礵Ƥޤ


ǾΥѥեޥ󥹤٤ݤϡ SWITCH ƤƤϤǤ礦



SWITCH Υȥ

Amazonڡ
https://www.amazon.co.jp/dp/B0095GON76

HYPER SWITCH Ϥ顪
https://www.amazon.co.jp/dp/B012QKWVMQ


iStock_000005716223XSmall

ΥڡΥȥåץ